GLP1R and type 2 diabetes mellitus: The newer glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors, in combination with good dietary support, have potential to enable more people with type 2 diabetes to achieve weight loss and/or normoglycaemia while avoiding hypoglycaemia, with renoprotection and decreased risks of CVD and mortality [7].